The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.
By Nicolas Touchot and Marie Cassese
In the last few years, market access has turned into one of the most debated and researched topics in the...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
